List of works - Ken Ogasawara

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

scientific article published on 01 April 2022

Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney.

scientific article

Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach

scientific article published on 14 June 2020

Characterization of the Basal promoter element of human organic cation transporter 2 gene.

scientific article published on 21 February 2007

Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016

scientific article published on 03 December 2018

Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

scientific article

Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1

scientific article

Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects

scientific article published on 06 June 2019

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

scientific article published on 04 April 2020

Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics

scientific article published on 19 December 2017

Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.

scientific article published in January 2010

Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.

scientific article

Impact of regulatory polymorphisms in organic anion transporter genes in the human liver.

scientific article published in August 2009

Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation

scientific article published on 28 May 2008

Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients

scientific article published on September 2013

Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS.

scientific article

Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus

scientific article

Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver

scientific article published on 11 June 2018

Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis.

scientific article

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

scientific article published on 24 May 2020

Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus

scientific article

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

scientific article published on 16 June 2016

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

scientific article

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.

scientific article published on 27 April 2017

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

scientific article published on 01 February 2020

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

scientific article published on 23 August 2019

Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics

scientific article published on 01 February 2019

List of works by Ken Ogasawara

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney.

Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach

Characterization of the Basal promoter element of human organic cation transporter 2 gene.

Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016

Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1

Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics

Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.

Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.

Impact of regulatory polymorphisms in organic anion transporter genes in the human liver.

Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation

Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients

Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS.

Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus

Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver

Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis.

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics